Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
AbbVie said its Phase 3 CERVINO trial for investigational etentamig in relapsed/refractory multiple myeloma met both primary endpoints, with etentamig achieving higher objective response results in topline findings.
AbbVie says Phase 3 CERVINO TOPLINE results are positive, with etentamig showing improved response rate and progression-free survival in relapsed/refractory multiple myeloma.